SG10201806108TA - Binding proteins and methods of use thereof - Google Patents

Binding proteins and methods of use thereof

Info

Publication number
SG10201806108TA
SG10201806108TA SG10201806108TA SG10201806108TA SG10201806108TA SG 10201806108T A SG10201806108T A SG 10201806108TA SG 10201806108T A SG10201806108T A SG 10201806108TA SG 10201806108T A SG10201806108T A SG 10201806108TA SG 10201806108T A SG10201806108T A SG 10201806108TA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
beta klotho
antibodies
present disclosure
Prior art date
Application number
SG10201806108TA
Inventor
Kalyani Mondal
Betty Li
Yu Chen
Taruna Arora
Hugo Matern
Wenyan Shen
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of SG10201806108TA publication Critical patent/SG10201806108TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

BINDING PROTEINS AND METHODS OF USE THEREOF The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use. Figure 1A and 1B
SG10201806108TA 2014-01-24 2015-01-23 Binding proteins and methods of use thereof SG10201806108TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931531P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
SG10201806108TA true SG10201806108TA (en) 2018-08-30

Family

ID=53678415

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806108TA SG10201806108TA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof
SG11201606018UA SG11201606018UA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606018UA SG11201606018UA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Country Status (29)

Country Link
US (5) US9738716B2 (en)
EP (2) EP3097122B9 (en)
JP (3) JP6837840B2 (en)
KR (1) KR102489475B1 (en)
CN (1) CN106662577B (en)
AU (1) AU2015209131B2 (en)
CA (1) CA2937898A1 (en)
CL (1) CL2016001868A1 (en)
CY (1) CY1123163T1 (en)
DK (1) DK3097122T3 (en)
ES (1) ES2808340T3 (en)
HR (1) HRP20200881T1 (en)
HU (1) HUE050279T2 (en)
IL (1) IL246921B (en)
LT (1) LT3097122T (en)
MX (1) MX2016009555A (en)
MY (1) MY191944A (en)
NZ (1) NZ722377A (en)
PE (1) PE20170256A1 (en)
PH (1) PH12016501644B1 (en)
PL (1) PL3097122T3 (en)
PT (1) PT3097122T (en)
RS (1) RS60593B1 (en)
RU (1) RU2701434C2 (en)
SG (2) SG10201806108TA (en)
SI (1) SI3097122T1 (en)
UA (1) UA119863C2 (en)
WO (1) WO2015112886A2 (en)
ZA (1) ZA201605151B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102077721B1 (en) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions, Uses and Methods for Treatment of Metabolic Disorders and Diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (en) 2012-12-27 2018-11-27 恩格姆生物制药公司 Method for adjusting bile acid homeostasis and treating bile acid disorder and disease
JP2016506914A (en) 2013-01-16 2016-03-07 アンセルムＩｎｓｅｒｍ Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
RU2701434C2 (en) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Binding proteins and methods for use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (en) 2014-09-08 2018-04-11 国立大学法人大阪大学 Preventive or therapeutic agent for demyelinating disease
EP3209681A4 (en) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) * 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN108350072B (en) 2015-08-03 2022-05-24 诺华股份有限公司 Methods of treating FGF 21-associated disorders
TWI750133B (en) 2015-08-24 2021-12-21 美商葛蘭素史密斯克萊有限責任公司 Biopharmaceutical compositions
CA2997290A1 (en) 2015-09-24 2017-03-30 Genentech, Inc. Methods for the treatment of epilepsy
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
BR112018009064A8 (en) * 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co pd-11 antibody, antigen binding fragment thereof and medical application thereof
DK3481859T3 (en) 2016-07-07 2022-04-25 Pfizer Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US20240076332A1 (en) * 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line
AU2018218557B9 (en) 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
BR112020005459A2 (en) * 2017-09-20 2020-09-29 Pfizer Inc. treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory Methods for treating pancreatitis
WO2020218823A1 (en) * 2019-04-22 2020-10-29 연세대학교 산학협력단 Composition containing, as active ingredient, klotho proteins or genes encoding same
CN110616195B (en) * 2019-10-11 2021-05-04 江南大学 Metformin monoclonal antibody hybridoma cell strain and application thereof
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
US20220010021A1 (en) * 2020-07-02 2022-01-13 Sanofi FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
CN113444730A (en) * 2021-03-17 2021-09-28 昆明市延安医院 Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
JP2024517844A (en) 2021-05-04 2024-04-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Multispecific FGF21 receptor agonists and uses thereof
CN117897405A (en) * 2021-06-30 2024-04-16 得克萨斯大学体系董事会 Polypeptide targeting CD 70-positive cancer
WO2023046071A1 (en) 2021-09-23 2023-03-30 江苏恒瑞医药股份有限公司 Anti-klb antibodies and uses
WO2023125745A1 (en) * 2021-12-30 2023-07-06 上海津曼特生物科技有限公司 ANTI-βKLOTHO ANTIBODY AND USE THEREOF
CN115197300B (en) * 2022-05-17 2023-05-05 四川大学华西第二医院 Protein with non-sequence specificity and high affinity for RNA and application thereof

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
JP3242916B2 (en) 1990-12-14 2001-12-25 セル ジェネシス，インコーポレイティド Chimeric chains for receptor-related signal transduction systems
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (en) 1991-11-21 1993-06-16 Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CN1117155C (en) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 Novel compounds
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DK0805628T3 (en) 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specific transepithelial transport of immunogens
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
CN1167795C (en) 1996-12-26 2004-09-22 协和发酵工业株式会社 Novel peptide, novel DNA, and novel antibody
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20060246540A1 (en) 1997-08-26 2006-11-02 Ashkenazi Avi J Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US6806352B2 (en) 1997-09-17 2004-10-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030054400A1 (en) 1997-09-17 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030113718A1 (en) 1997-09-17 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
EP1042343B1 (en) 1997-11-03 2008-01-23 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US7390879B2 (en) 1999-06-15 2008-06-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
JP2001072607A (en) 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd New capillary endothelial function improvement
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
JP4651893B2 (en) 1999-11-19 2011-03-16 社団法人芝蘭会 Novel polypeptide, novel DNA, novel antibody, and novel genetically modified animal
DE10160151A1 (en) 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
WO2001049740A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
US20010044525A1 (en) 2000-01-05 2001-11-22 Conklin Darrell C. Novel FGF Homolog zFGF12
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
AU3976701A (en) 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20030180312A1 (en) 2000-02-22 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
AU2001245535A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
JP2002112772A (en) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd New polypeptide and its dna
US7223563B2 (en) 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
JP2004516013A (en) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド Compositions and methods for diagnosing and treating disorders associated with angiogenesis
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7164009B2 (en) 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7537902B2 (en) 2000-10-24 2009-05-26 Emory University Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
WO2002041911A2 (en) 2000-11-22 2002-05-30 Bayer Corporation Use of fgf-19 for inhibiting angiogenesis
US20020151496A1 (en) 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
DE10100588A1 (en) 2001-01-09 2002-07-18 Ribopharma Ag Inhibiting expression of target genes, useful e.g. for treating tumors, by introducing into cells two double-stranded RNAs that are complementary to the target
DE10100587C1 (en) 2001-01-09 2002-11-21 Ribopharma Ag Inhibiting expression of target genes, e.g. oncogenes, in cells, by introduction of complementary double-stranded oligoribonucleotide, after treating the cell with interferon
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JP2003334088A (en) 2002-05-22 2003-11-25 Pharma Design Inc HUMAN-DERIVED NEW Klotho-LIKE PROTEIN AND ITS GENE
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
MXPA04012243A (en) 2002-06-07 2005-02-25 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
WO2004026228A2 (en) 2002-09-18 2004-04-01 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2006240990A (en) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd Klotho protein and anti-klotho protein antibody and use of them
SI1641483T1 (en) 2003-06-12 2008-08-31 Lilly Co Eli Fusion proteins
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
JP4477013B2 (en) 2003-12-10 2010-06-09 イーライ リリー アンド カンパニー Fibroblast growth factor 21 mutein
DE602005016917D1 (en) 2004-05-13 2009-11-12 Lilly Co Eli FGF-21 FUSION PROTEIN
JP2006016323A (en) 2004-06-30 2006-01-19 Hiroshima Industrial Promotion Organization Physiologically active biomaterial
PT1789442E (en) 2004-09-02 2009-11-11 Lilly Co Eli Muteins of fibroblast growth factor 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1817335A2 (en) 2004-10-29 2007-08-15 Genentech, Inc. Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
WO2006048291A2 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
JP2006158339A (en) 2004-12-09 2006-06-22 Kyoto Univ betaKlotho GENE, Cyp7al GENE, AND THEIR USE
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007025085A2 (en) 2005-08-24 2007-03-01 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CA2637216A1 (en) 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
US8168169B2 (en) 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
CA2661332A1 (en) 2006-09-01 2008-03-13 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
WO2008085879A2 (en) 2007-01-03 2008-07-17 California Stem Cell, Inc. Stem cell growth media and methods of making and using same
KR20140012199A (en) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 Modified fgf-21 polypeptides and their uses
CA2682096A1 (en) 2007-04-02 2009-01-15 Genentech, Inc. Klotho beta
JP5187837B2 (en) 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 Method for activating receptor by cofactor and utilization of ligand activity
US7537903B2 (en) * 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
WO2008135993A1 (en) 2007-05-08 2008-11-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US10555963B2 (en) 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
US20120142546A1 (en) 2007-12-10 2012-06-07 The Johns Hopkins University Hypomethylated genes in cancer
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US20090226459A1 (en) 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
NZ579566A (en) 2008-03-19 2013-01-25 Ambrx Inc Modified fgf-21 polypeptides and their uses
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
EP2257814B1 (en) 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
FR2933702A1 (en) 2008-07-08 2010-01-15 Sanofi Aventis SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
US20100274362A1 (en) 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
DK3248610T3 (en) 2009-05-05 2024-01-15 Amgen Inc FGF21 MUTANTS AND USES THEREOF
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2437775A1 (en) 2009-06-04 2012-04-11 Novartis AG Fgf-21 for treating cancers
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
CN101993485B (en) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
CN102656266B (en) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 There is the chimeric fibroblast growth factor of the receptor-specific of change
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
WO2012031603A2 (en) 2010-09-09 2012-03-15 Danish Medical Consults Aps Airway administration of angiogenesis inhibitors
EA201370076A1 (en) 2010-09-22 2013-08-30 Амген Инк. IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
CN102464712A (en) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 Deletion human fibroblast growth factor 21 variant and conjugate thereof
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
AU2011348202A1 (en) 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
WO2012086809A1 (en) 2010-12-24 2012-06-28 独立行政法人産業技術総合研究所 Accurate and highly sensitive method for measuring activity of human fgf19 and agent for regulating activity of human fgf19
JP5977814B2 (en) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
EP2707718A1 (en) 2011-05-10 2014-03-19 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
CN103596980B (en) 2011-05-16 2017-08-08 霍夫曼-拉罗奇有限公司 FGFR1 activators and application method
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
CN103649386B (en) 2011-06-08 2015-12-23 索元生物医药（杭州）有限公司 The method and composition of prediction retinoid x receptor modulator activity
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
KR102077721B1 (en) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions, Uses and Methods for Treatment of Metabolic Disorders and Diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
JO3476B1 (en) 2011-09-26 2020-07-05 Novartis Ag Fusion proteins for treating metabolic disorders
TW201315742A (en) 2011-09-26 2013-04-16 Novartis Ag Dual fuction proteins for treating metabolic disorders
AR087973A1 (en) 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
SG11201401699WA (en) * 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
RU2014133547A (en) 2012-01-18 2016-03-10 Дженентек, Инк. WAYS OF APPLICATION OF FGF19 MODULATORS
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
JP2013194049A (en) 2012-03-23 2013-09-30 Kazuo Todokoro Composition and method for amplifying human hematopoietic stem cell
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013156920A1 (en) 2012-04-16 2013-10-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho variant polypeptides and uses thereof in therapy
WO2013173158A1 (en) 2012-05-15 2013-11-21 Eli Lilly And Company Therapeutic uses of fibroblast growth factor 21 proteins
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (en) 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
KR102163776B1 (en) 2012-07-11 2020-10-12 블루프린트 메디신즈 코포레이션 Inhibitors of the fibroblast growth factor receptor
AR092076A1 (en) 2012-08-22 2015-03-18 Lilly Co Eli HOMODIMERIC PROTEINS
KR20150043505A (en) 2012-09-07 2015-04-22 사노피 Fusion proteins for treating a metabolic syndrome
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (en) 2012-12-27 2018-11-27 恩格姆生物制药公司 Method for adjusting bile acid homeostasis and treating bile acid disorder and disease
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014152090A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
CN105828833A (en) 2013-10-21 2016-08-03 萨克生物研究学院 Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
RU2701434C2 (en) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Binding proteins and methods for use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3209681A4 (en) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
AU2017321286A1 (en) 2016-08-29 2019-03-07 NGM Biopharmaceuticals, Inc Methods for treatment of bile acid-related disorders

Also Published As

Publication number Publication date
EP3097122B1 (en) 2020-05-06
NZ722377A (en) 2022-09-30
UA119863C2 (en) 2019-08-27
RU2016130128A (en) 2018-02-27
US20210030857A1 (en) 2021-02-04
BR112016017248A2 (en) 2017-10-03
US11596676B2 (en) 2023-03-07
US20190106490A1 (en) 2019-04-11
MY191944A (en) 2022-07-20
CA2937898A1 (en) 2015-07-30
EP3097122A2 (en) 2016-11-30
ZA201605151B (en) 2020-12-23
EP3097122B9 (en) 2020-11-11
ES2808340T9 (en) 2021-03-05
US20230256070A1 (en) 2023-08-17
MX2016009555A (en) 2016-12-08
BR112016017248A8 (en) 2018-04-17
JP2022153375A (en) 2022-10-12
HRP20200881T1 (en) 2020-09-04
RU2016130128A3 (en) 2018-09-04
PT3097122T (en) 2020-07-21
RU2701434C2 (en) 2019-09-26
SG11201606018UA (en) 2016-08-30
SI3097122T1 (en) 2020-07-31
KR20160125381A (en) 2016-10-31
US20180100014A1 (en) 2018-04-12
WO2015112886A2 (en) 2015-07-30
US10093735B2 (en) 2018-10-09
HUE050279T2 (en) 2020-11-30
JP6837840B2 (en) 2021-03-10
ES2808340T3 (en) 2021-02-26
KR102489475B1 (en) 2023-01-20
AU2015209131B2 (en) 2020-06-25
CN106662577B (en) 2020-07-21
PL3097122T3 (en) 2020-10-19
WO2015112886A3 (en) 2015-10-01
LT3097122T (en) 2020-07-27
US9738716B2 (en) 2017-08-22
EP3097122A4 (en) 2017-09-20
US10744191B2 (en) 2020-08-18
RS60593B1 (en) 2020-08-31
AU2015209131A1 (en) 2016-08-11
PH12016501644A1 (en) 2016-11-07
EP3738981A1 (en) 2020-11-18
PH12016501644B1 (en) 2016-11-07
CL2016001868A1 (en) 2017-07-21
JP2017507652A (en) 2017-03-23
JP2020169173A (en) 2020-10-15
CN106662577A (en) 2017-05-10
IL246921A0 (en) 2016-09-29
US20150210764A1 (en) 2015-07-30
IL246921B (en) 2019-09-26
JP7436571B2 (en) 2024-02-21
DK3097122T3 (en) 2020-08-10
PE20170256A1 (en) 2017-04-22
CY1123163T1 (en) 2021-10-29

Similar Documents

Publication Publication Date Title
PH12016501644B1 (en) Binding proteins and methods of use thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017502180A1 (en) Tau-binding antibodies
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2018003689A (en) Pd-1 binding proteins and methods of use thereof.
MX2017005920A (en) Anti-tim3 antibodies and methods of use.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
PH12017502207A1 (en) Tau-binding antibodies
MX2017007941A (en) Anti-axl antagonistic antibodies.
MX2015012326A (en) Anti-crth2 antibodies and their use.
MA40527A (en) Antigen binding proteins that bind cxcr5
WO2017019957A3 (en) Binding proteins and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2016015280A (en) Anti-brdu antibodies and methods of use.
MX2016014726A (en) Her1 antigen binding proteins binding to the beta-hairpin of her1.
IL266576A (en) Antibody specifically binding to pauf protein, and use thereof
NZ744340A (en) Anti-jagged1 antibodies and methods of use